These ligands in turn bind to Notch receptors (Notch1 and 4) in the adjacent cells, which results in sequential proteolytic cleavages by ADAM and γ-secretase, which release the NICD into the nucleus.

With this unique approach, Cellestia has been able to close an important gap in the quest to break multi-drug resistance in cancer, as CB-103 can effectively take out the Notch/CSL–NICD–MAML ...